Background
Methods
Setting and study design
Subjects
Sample size
Inclusion criteria
Exclusion criteria
Intervention
LA treatment
TA treatment
Follow-up
Outcome
Data analysis
Results
Demographic information | Control group (n = 38) | Treatment group (n = 39) |
P value | ||
---|---|---|---|---|---|
Mean ± SD | Range | Mean ± SD | Range | ||
Age (year) | 31.7 ± 6.2 | 21–44 | 31.4 ± 7.0 | 24–50 | 0.84 |
Duration (month) | 32.4 ± 39.3 | 3–156 | 24.3 ± 27.9 | 3–120 | 0.31 |
NIH-CPSI (total) | 26.7 ± 4.9 | 17–37 | 26.6 ± 5.8 | 12–37 | 0.89 |
Pain or discomfort | 11.1 ± 2.8 | 5–17 | 11.1 ± 3.1 | 4–16 | 1.0 |
Urination | 5.8 ± 2.8 | 0–10 | 5.4 ± 3.3 | 0–11 | 0.52 |
Impact of symptoms | 5.0 ± 1.0 | 2–6 | 5.2 ± 1.1 | 3–6 | 0.34 |
Quality of life | 4.9 ± 1.2 | 2–6 | 4.9 ± 1.1 | 3–6 | 0.84 |
CM symptom | 15.3 ± 7.3 | 6–34 | 14.0 ± 5.0 | 6–24 | 0.36 |
Treatment with LA improved the NIH-CPSI scores
Scores | TA (n = 38) | LA (n = 39) | ||||
---|---|---|---|---|---|---|
Pre-treatment | Post-treatment | Follow up | Pre-treatment | Post-treatment | Follow up | |
NIH-CPSI (total) | 26.7 ± 4.9 | 22.6 ± 5.2* | 17.3 ± 9.1* | 26.6 ± 5.8 | 17.0 ± 6.0*△
| 9.4 ± 8.6*△
|
Pain or discomfort | 11.1 ± 2.8 | 9.0 ± 2.7* | 6.6 ± 4.0* | 11.1 ± 3.1 | 6.5 ± 3.0*△
| 3.3 ± 3.8*△
|
Urination | 5.8 ± 2.8 | 5.0 ± 2.0* | 3.8 ± 3.1* | 5.4 ± 3.3 | 3.5 ± 2.6*△
| 2.1 ± 2.6* |
Impact of symptoms | 5.0 ± 1.0 | 4.4 ± 1.2* | 3.4 ± 1.8* | 5.2 ± 1.1 | 3.5 ± 1.6*△
| 2.0 ± 1.7*△
|
Quality of life | 4.9 ± 1.2 | 4.4 ± 1.4* | 3.5 ± 1.7* | 4.9 ± 1.1 | 3.5 ± 1.3*△
| 2.0 ± 1.6*△
|
CM symptom | 15.3 ± 7.3 | 12.1 ± 5.7* | - | 14.0 ± 5.0 | 8.4 ± 5.3*△
| - |
LA group had greater improvement in clinical efficacy
TA | LA | ||
---|---|---|---|
(n = 38) | (n = 39) |
p-value | |
Clinical efficacy, No. (%) | |||
Effective | 8 (21.1) | 22 (56.4) | 0.001 |
Ineffective | 30 (78.9) | 17 (43.6) |